The Response Assessment in Neuro-Oncology Working Group has analysed the role of clinically established PET methods in the diagnostic assessment of brain tumours. The group emphasizes the clinical value of PET imaging, particularly amino acid PET imaging, over conventional MRI, and recommends its use at every stage of management.
This is a preview of subscription content, log in via an institution to check access.
References
Tovi, M., Hartman, M., Lilja, A. & Ericsson, A. MR imaging in cerebral gliomas. Tissue component analysis in correlation with histopathology of whole-brain specimens. Acta Radiol. 35, 495–505 (1994).
Ryken, T. C. et al. The role of imaging in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 118, 435–460 (2014).
Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963–1972 (2010).
Albert, N. L. et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. http://dx.doi.org/10.1093/neuonc/now058 (2016).
Rapp, M. et al. Clinical value of O-(2-[18F]-fluoroethyl)-L-tyrosine positron emission tomography in patients with low-grade glioma. Neurosurg. Focus 34, E3 (2013).
Galldiks, N. et al. The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol. 17, 1293–1300 (2015).
Singhal, T., Narayanan, T. K., Jain, V., Mukherjee, J. & Mantil, J. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol. Imaging Biol. 10, 1–18 (2008).
Langen, K. J., Tonn, J. C., Weller, M. & Galldiks, N. Letter to the editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460]. J. Neurooncol. 120, 665–666 (2014).
Swiss Agency for Therapeutic Products. New registrations, products for use in humans. J. Swissmed. 13, 651 (2014).
Heinzel, A., Stock, S., Langen, K. J. & Muller, D. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. Eur. J. Nucl. Med. Mol. Imaging 39, 1089–1096 (2012).
Author information
Authors and Affiliations
Contributions
Both authors contributed equally to all aspects of the article.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Langen, KJ., Watts, C. Amino acid PET for brain tumours — ready for the clinic?. Nat Rev Neurol 12, 375–376 (2016). https://doi.org/10.1038/nrneurol.2016.80
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2016.80
- Springer Nature Limited
This article is cited by
-
A bis-boron boramino acid PET tracer for brain tumor diagnosis
European Journal of Nuclear Medicine and Molecular Imaging (2024)
-
MGMT promoter methylation status shows no effect on [18F]FET uptake and CBF in gliomas: a stereotactic image-based histological validation study
European Radiology (2022)
-
DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis
Strahlentherapie und Onkologie (2022)
-
Static 18F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status
European Radiology (2021)
-
Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics
European Journal of Nuclear Medicine and Molecular Imaging (2021)